Pulling out the stops on personalised medicine
This article was originally published in Clinica
Executive Summary
Personalised medicine is set to become big business. Biopharmaceutical companies of all sizes have personalised medicine projects in their early pipeline. Regulators in the EU and the US are drafting guidelines on biomarkers and companion diagnostics, and government funding is being made available for collaborative industry/academia projects.